The effectiveness of a psychological intervention targeting bereaved caregivers of cancer patients

Submission date	Recruitment status	[X] Prospectively registered
01/12/2024	Recruiting	[X] Protocol
Registration date	Overall study status	Statistical analysis plan
04/12/2024	Ongoing	☐ Results
Last Edited	Condition category	Individual participant data
19/05/2025	Other	[X] Record updated in last year

Plain English summary of protocol

Background and study aims

An increasing number of patients with advanced cancer are receiving home palliative care, provided in most cases by informal caregivers who are exposed to significant demands on their time, physical energy and mental resources. While many studies proposed interventions targeting cancer caregivers, most of them focus on caregivers' distress, overlooking positive outcomes, such as Resilience and Post Traumatic growth. This study aims to test the feasibility, acceptability and effectiveness of an adapted version of the EMPOWER (Enhancing & Mobilizing the POtential for Wellness & Emotional Resilience) intervention for protecting Cypriot bereaved cancer caregivers against distress and enhancing their positive outcomes.

Who can participate?

The participants of the study will be Greek-speaking bereaved caregivers of cancer patients. Eligible for participation will be those experienced the loss of a loved one within the last 18 months and three months have passed since the loss and at risk for Prolonged Grief. Participation is allowed regardless of gender, career orientation and family status, with the only requirement being age, meaning adults over 18 years old. Participation in the study is not allowed for individuals who lost a non-adult son/daughter to cancer, those with low grief risk, people suffering from severe mental illness (i.e. psychosis, bipolar, severe depression, personality disorder) or substance abuse disorder, or dementia (self-report of previous diagnosis), caregivers with substantial risk of suicidality and those receiving external psychological support in individual or group format

What does the study involve?

The study will be a Trial with bereaved caregivers. The intervention group will receive six weekly sessions that take approximately 45–60 min each to complete. Following the 6 weekly sessions, two booster sessions will be delivered by phone, 2 and 4 weeks after the end of the intervention. Booster sessions will focus on reviewing the skills taught in the six previous sessions and will last approximately 30 minutes each.

Participants of the control group will receive a 1.5-hour psycho-educational workshop. Caregivers will be provided information regarding bereavement characteristics, factors that

influence bereavement outcomes (risk vulnerability), common emotional-psychological reactions and thoughts after the loss, basic bereavement models and theories, adaptation to loss, and information on when to seek professional support and access to further care

What are the possible benefits and risks of participating?

Participants in the intervention group will benefit from receiving psychological support if found to be at risk for developing complicated grief, based on the screening assessment. Participants in the control group will have the opportunity to receive the intervention after completion of the study if they wish to do so, as PASYKAF's services will keep running as long as there are individuals in need. Also, participants will contribute to the knowledge around what works for bereavement.

Bereavement has not been investigated enough, especially in Greek-speaking population. In addition, the scientific knowledge and experience on the specific population is limited. As the results of the study are expected to confirm our hypotheses, regarding superiority of the intervention for decreasing distress, protecting against prolonged grief and increasing resilience, Post Traumatic Growth and experiential acceptance, bereaved cancer caregivers will benefit by having an intervention that helps in the decrease of the symptoms caused by the loss of a loved one

Considering the sensitivity of the topic, there is a possibility of emotional discomfort. Nonetheless, appropriate and necessary measures and procedure will be followed. In case that suicidal ideation is detected during the screening process, participants will be referred to the clinical psychologists of PASYKAF for mental health first aid and further assessment to palliate real suicide risk.

In case that any of the participants feel anxiety or discomfort during the assessment or intervention, they will interrupt their participation to the study, and continue their therapeutic process with one of the psychologists of PASYKAF.

In addition, all the participants will be provided with a list including information (telephone numbers and address) of the hospitals and the Registered Clinical and Counselling Psychologists all over Cyprus.

Where is the study run from?

The study will take place at the premises of the Cyprus Association of Cancer Patients and Friends (PASYKAF) all over Cyprus (Nicosia, Larnaca, Limassol, Ammochostos, and Paphos). PASYKAF is an association offering Supportive and Home Palliative Care, supporting cancer patients and caregivers at all stages of the illness. It provides medical and nursing home care services, psychological, social support, rehabilitation services, physiotherapy during treatment, remission, and particularly, during the palliative and end of life care stage.

When is the study starting and how long it is expected to run for? November 2024 to June 2026

Who is funding the study? Investigator initiated and funded

Who is the main contact?

Dr Eleni Petkari, epetkari@uma.es

Contact information

Type(s)

Public, Scientific, Principal Investigator

Contact name

Dr Eleni Petkari

ORCID ID

http://orcid.org/0000-0002-9261-6253

Contact details

University of Malaga C/. Doctor Ortiz Ramos, 12 Malaga Spain 29010 +357 22 713000 epetkari@uma.es

Additional identifiers

EudraCT/CTIS number

Nil known

IRAS number

ClinicalTrials.gov number

Nil known

Secondary identifying numbers

Nil known

Study information

Scientific Title

The effectiveness of a psychological intervention targeting bereaved caregivers of cancer patients: study protocol for the EMPOWER-Cancer-Grief RCT

Acronym

EMPOWER-Cancer-Grief

Study objectives

The primary hypotheses of the study are:

- 1. The intervention will be feasible and show good levels of acceptability among the Cypriot cancer caregivers
- 2. Compared to usual care, intervention group caregivers will report reduced distress (i.e. depression and anxiety symptoms) and reduced risk for prolonged grief after the intervention.
- 3. Caregivers in the intervention group will also show higher levels of experiential acceptance, resilience and post Traumatic Growth (PTG) after the intervention.

Ethics approval required

Ethics approval required

Ethics approval(s)

Approved 18/11/2024, Cyprus National Bioethics Committee (22 Laertou Street, Nicosia, 2365, Cyprus; +357 22-809038; cnbc@bioethics.gov.cy), ref: EEBK/EP/2024/69

Study design

Phase 1: open interventional trial, Phase 2: multisite randomized controlled trial

Primary study design

Interventional

Secondary study design

Randomised controlled trial

Study setting(s)

Charity/Voluntary sector, Workplace

Study type(s)

Prevention, Quality of life, Treatment

Participant information sheet

Not available in web format, please use the contact details to request a patient information sheet.

Health condition(s) or problem(s) studied

Bereaved caregivers of cancer patients

Interventions

The study will consist of two phases. Phase 1 will involve two steps: an open trial with 10 bereaved caregivers who will receive the intervention and then provide feedback on their experience; and a manual refinement process that will involve 5 caregivers and 5 mental health clinicians. They will be provided with the manual and asked for feedback on the content, format, and language of the EMPOWER-Cancer-Grief Intervention. The feedback given in phase 1, will be used to adjust the intervention.

Phase 2 will involve a multisite Randomized Controlled Trial using a 2-group design with one intervention and one control group, aiming to enroll up to 50 bereaved caregivers. The randomisation process will be carried out using an online tool.

The EMPOWER-Cancer-Grief intervention will be administered by four trained psychologists, one for each city. The intervention aims to reduce experiential avoidance (i.e., the tendency to avoid unpleasant feelings) and protect caregivers from negative outcomes, such as prolonged grief disorder or Post Traumatic Stress disorder (PTSD) following the patient's death. It is a blended intervention combining techniques from Cognitive behavioural and Acceptance and commitment Therapy, aiming to teach coping skills that will help caregivers tolerate, minimize, and deal with the death of their loved one.

The intervention includes active listening, breathing techniques and mindfulness, experiential exercises, psychoeducation on trauma, common reactions and emotional functioning. It uses imaginal dialogue and teaches coping techniques such as problem-focused strategies and meaning making.

It consists of six weekly sessions that take approximately 45–60 min each to complete. Following the 6 weekly sessions, two booster sessions will be delivered by phone, 2 and 4 weeks after the end of the intervention. Booster sessions will focus on reviewing the skills taught in the six previous sessions and will last approximately 30 minutes each.

Participants of the control group will receive a 1.5-hour psycho-educational workshop. Caregivers will be provided information regarding bereavement characteristics, factors that influence bereavement outcomes (risk vulnerability), common emotional-psychological reactions and thoughts after the loss, basic bereavement models and theories, adaptation to loss, and information on when to seek professional support and access to further care.

Intervention Type

Behavioural

Primary outcome measure

- 1. Demographics are measured using an ad-hoc questionnaire at Screening, pre-intervention
- 2. Grief is measured using the Texas Revised Inventory of Grief (TRIG) at Screening, preintervention, post-intervention, one-month follow-up, and three-month follow-up
- 3. Prolonged grief is measured using the Prolonged Grief/PG-13 (Prigerson et al., 2009) at Screening, pre-intervention, post-intervention, one-month follow-up, and three-month follow-up
- 4. Suicide risk is measured using the Suicide Risk Scale (SRS) at Screening
- 5. Depression and anxiety are measured using the Depression-Anxiety-Stress Scale (DASS-21) at pre-intervention, post-intervention, one-month follow-up, and three-month follow-up
- 6. Resilience is measured using the CD-RISC (Connor & Davidson, 2003) at pre-intervention, post-intervention, one-month follow-up, and three-month follow-up
- 7. Post-traumatic growth is measured using the PTGI (Tedeschi & Calhoun, 1996) at pre-intervention, post-intervention, one-month follow-up, and three-month follow-up
- 8. Experiential avoidance is measured using the AAQ II (Bond et al., 2011) at pre-intervention, post-intervention, one-month follow-up, and three-month follow-up

Secondary outcome measures

There are no secondary outcome measures

Overall study start date

01/11/2024

Completion date

30/06/2026

Eligibility

Key inclusion criteria

- 1. Having lost a loved one within the last 18 months and three months have passed since the loss
- 2. Cancer-related loss
- 3. Aged from 18 years
- 4. Being at risk for Prolonged Grief based on the PG-13-R scores (Prolonged Grief Disorder Revised; Prigerson et al.,2021) and on the TRIG scores (Texas Revised Inventory of Grief Greek version; Christodoulou et al. under preparation)
- 5. Able to communicate fluently in Greek.

Participant type(s)

Carer

Age group

Adult

Lower age limit

18 Years

Upper age limit

75 Years

Sex

Both

Target number of participants

50

Key exclusion criteria

- 1. Having lost a non-adult son/daughter to cancer
- 2. Low grief risk based on PG-13-R scores and TRIG scores
- 3. Suffering from severe mental illness (i.e. psychosis, bipolar, severe depression, personality disorder) or substance abuse disorder, or dementia (self-report of previous diagnosis)
- 4. Substantial risk of suicidality (Based on SRS Suicide Risk Scale; Plutchik et al, 1989)
- 5. Receiving external psychological support in individual or group format

Date of first enrolment

02/06/2025

Date of final enrolment

30/03/2026

Locations

Countries of recruitment

Cyprus

Study participating centre EUROPEAN UNIVERSITY OF CYPRUS

6, Diogenes 2404 Engomi Nicosia Cyprus

P.O. Box: 22006, 1516

Sponsor information

Organisation

European University Cyprus

Sponsor details

6, Diogenes 2404 Engomi P.O. Box: 22006, 1516 Nicosia Cyprus 22006 +357 22 713000 M.Vryonides@euc.ac.cy

Sponsor type

University/education

Website

https://www.euc.ac.cy/

ROR

https://ror.org/04xp48827

Funder(s)

Funder type

Other

Funder Name

Investigator initiated and funded

Results and Publications

Publication and dissemination plan

At least two scientific articles will be produced, one on the study protocol and at least one on the outcomes. These will be sent to peer-reviewed journals related to Psycho-oncology and Positive psychology. A dissemination event will be organised upon ending the study aiming at acknowledging the findings and inform the general public and the stakeholders

Intention to publish date

30/06/2026

Individual participant data (IPD) sharing plan

IPD will be uploaded at the osf.io platform

IPD sharing plan summary

Data sharing statement to be made available at a later date

Study outputs

Output typeDetailsDate createdDate addedPeer reviewed?Patient-facing?Protocol article14/05/202519/05/2025YesNo